lamivudine has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, T; Cui, Y; Kong, H; Song, Y; Zhao, H | 1 |
| Augustine, J; Chen, M; Cunning, R; Harkin, K; Pavlou, S; Stitt, AW; Xu, H | 1 |
2 other study(ies) available for lamivudine and Alloxan Diabetes
| Article | Year |
|---|---|
Targeted P2X7/NLRP3 signaling pathway against inflammation, apoptosis, and pyroptosis of retinal endothelial cells in diabetic retinopathy.
Topics: Adenosine Triphosphate; Animals; Anti-Inflammatory Agents; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelial Cells; Inflammasomes; Inflammation; Lamivudine; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Pyroptosis; Signal Transduction | 2022 |
Attenuating Diabetic Vascular and Neuronal Defects by Targeting P2rx7.
Topics: Animals; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Electroretinography; Fluorescent Antibody Technique; Gene Expression; Immunohistochemistry; Lamivudine; Male; Mice; Purinergic P2X Receptor Antagonists; Receptors, Purinergic P2X7; Retinal Neurons; Retinal Vessels; Tomography, Optical Coherence | 2019 |